ICU Medical, Inc. $ICUI Holdings Decreased by WCM Investment Management LLC

WCM Investment Management LLC cut its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 1.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 236,623 shares of the medical instruments supplier’s stock after selling 2,761 shares during the quarter. WCM Investment Management LLC’s holdings in ICU Medical were worth $31,192,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ICUI. GAMMA Investing LLC raised its position in ICU Medical by 27.2% in the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 153 shares in the last quarter. Blue Trust Inc. raised its position in ICU Medical by 23.0% in the first quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier’s stock worth $111,000 after acquiring an additional 150 shares in the last quarter. United Services Automobile Association bought a new stake in ICU Medical in the first quarter worth about $218,000. Johnson Investment Counsel Inc. raised its position in ICU Medical by 17.7% in the second quarter. Johnson Investment Counsel Inc. now owns 1,699 shares of the medical instruments supplier’s stock worth $225,000 after acquiring an additional 256 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in ICU Medical in the first quarter worth about $235,000. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Trading Down 0.9%

Shares of ICUI opened at $116.29 on Thursday. The business’s 50-day moving average price is $123.61 and its 200 day moving average price is $130.35. The stock has a market capitalization of $2.87 billion, a P/E ratio of -76.51 and a beta of 0.83. ICU Medical, Inc. has a 1-year low of $107.00 and a 1-year high of $196.26. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, beating the consensus estimate of $1.44 by $0.66. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The company had revenue of $543.57 million for the quarter, compared to analysts’ expectations of $543.33 million. During the same quarter in the previous year, the business posted $1.56 EPS. The business’s revenue for the quarter was down 8.0% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Insider Activity

In other ICU Medical news, Director David C. Greenberg bought 1,200 shares of the stock in a transaction on Wednesday, August 27th. The shares were bought at an average price of $126.42 per share, with a total value of $151,704.00. Following the purchase, the director directly owned 7,960 shares in the company, valued at $1,006,303.20. The trade was a 17.75% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Vivek Jain bought 21,929 shares of the stock in a transaction on Thursday, August 14th. The shares were acquired at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the purchase, the chief executive officer owned 130,149 shares in the company, valued at approximately $14,686,013.16. This represents a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Piper Sandler boosted their price target on shares of ICU Medical from $145.00 to $153.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Raymond James Financial dropped their price target on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research report on Friday, August 8th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Friday, September 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, ICU Medical presently has a consensus rating of “Moderate Buy” and an average price target of $181.00.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.